NCT02225327View on ClinicalTrials.gov

MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

January 31, 2014

Conditions
Influenza, HumanPneumococcal Infections
Interventions
BIOLOGICAL

Fluad alone

Fluad

BIOLOGICAL

Fluad and PPV23 on the different arms

Fluad and Prodiax

BIOLOGICAL

Fluad and PPV23 on the same arm

Fluad and Prodiax

BIOLOGICAL

PPV23 alone

Prodiax

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Korea University Guro Hospital

OTHER